Regenera to list in early June
Wednesday, 19 May, 2004
The CEO of Perth-based biotech Regenera, Tony Fitzgerald, said today that he expected the company’s offer to close next week, oversubscribed, ready for a June listing.
Regenra plans to raise AUD$8 million to develop its therapy for age related macular degeneration AMD – a condition in which damage to the retina causes visual impairment. The therapy involves injecting a steroid, triamciolone acetomide, into the back of the eye every six months.
“We have had a very good response in a difficult market,” said Fitzgerald. He said there had been significant Australian investment and that a number of international opthamologists were also supporting the company.
Fitzgerald plans to gain both TGA approval and an international licence for Regenera's product, possibly as a co-therapy with another AMD treatment.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
